Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review

Satoshi Takanashi; Yuko Kaneko; Tsutomu Takeuchi

doi:10.1080/14397595.2021.1906505

Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review

Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi

研究成果: Article › 査読

本文言語	English
ジャーナル	Modern rheumatology
DOI	https://doi.org/10.1080/14397595.2021.1906505
出版ステータス	Accepted/In press - 2021

ASJC Scopus subject areas

医学（全般）

文献へのアクセス

10.1080/14397595.2021.1906505

他のファイルとリンク

引用スタイル

@article{e5fc1da87dc14a96af26cb090211dd22,

title = "Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review",

author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",

note = "Funding Information: S.T. reports no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharmaceutical Co., Ltd, Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd, Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.",

year = "2021",

doi = "10.1080/14397595.2021.1906505",

language = "English",

journal = "Japanese Journal of Rheumatology",

issn = "1439-7595",

publisher = "Springer Japan",

}

TY - JOUR

T1 - Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis

T2 - A literature review

AU - Takanashi, Satoshi

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

N1 - Funding Information: S.T. reports no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharmaceutical Co., Ltd, Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd, Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85104492804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104492804&partnerID=8YFLogxK

U2 - 10.1080/14397595.2021.1906505

DO - 10.1080/14397595.2021.1906505

M3 - Article

C2 - 33769925

AN - SCOPUS:85104492804

JO - Japanese Journal of Rheumatology

JF - Japanese Journal of Rheumatology

SN - 1439-7595

ER -